Advertisement

Pharmaceutical Chemistry Journal

, Volume 42, Issue 12, pp 670–673 | Cite as

Antitumor activity of polycyano-substituted carbo- and heterocycles prepared from 3-(2,2-dialkylhydrazino)-4-R-1,1,2,2-tetracyanocyclopentanes

  • V. P. Sheverdov
  • O. V. Ershov
  • O. E. Nasakin
Search for New Drugs

Anticancer activity tests have been carried out at the National Cancer Institute (USA) on a series of polycyano-substituted carbo- and heterocyclic compounds synthesized from 3-(2,2-dialkylhydrazino)-4-R-1,1,2,2-tetracyanocyclopentanes. It is established that 1,1,2,2-tetracyano-substituted derivatives are the most active, showing a high activity comparable with that of reference drugs with respect to colon, ovarian, prostate, and renal cancer. The antitumor effect of the investigated compounds is explained by the presence of dialkylhydrazino- and 1,1,2,2-tetracyanoethyl moieties in their structures.

Keywords

Antitumor Activity Letrozole Bicalutamide Dicarb Onitrile Linamarin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    V. V. Plemenkov, Introduction to the Chemistry of Natural Compounds [in Russian], Kazan (2001), pp. 59–60.Google Scholar
  2. 2.
    K. Hinterding, A. Knebel, P. Herrlich, and H. Waldmann, Bioorg. Med. Chem., 6, 1153–1162 (1998).PubMedCrossRefGoogle Scholar
  3. 3.
    E. Poradosu, A. Gazit, H. Reuveni, and A. Levitzki, Bioorg. Med. Chem., 7, 1727–1736 (1999).PubMedCrossRefGoogle Scholar
  4. 4.
    S. C. MacTough, S. J. DeSolms, A. W. Shaw, et al., Bioorg. Med. Chem., 9, 1257–1260 (2001).Google Scholar
  5. 5.
    N. Zhang, B. Wu, D. Powell, et al., Bioorg. Med. Chem., 8, 2825–2828 (2000).Google Scholar
  6. 6.
    M. Recanatini and A. Gavalli, Bioorg. Med. Chem., 6, 377–388 (1998).PubMedCrossRefGoogle Scholar
  7. 7.
    A. Gavalli, G. Greco, E. Novellino, and M. Recanatini, Bioorg. Med. Chem., 8, 2771–2780 (2000).CrossRefGoogle Scholar
  8. 8.
    M. Stockley, W. Clegg, G. Fontana, et al., Bioorg. Med. Chem., 9, 2837–2841 (2001).Google Scholar
  9. 9.
    M. D. Mashkovskii, Drugs [in Russian], RIA Novaya Volna, Moscow (2007), pp. 981, 989, 990, 1013, 1014.Google Scholar
  10. 10.
    E. C. Taylor and R. W. Hendess, J. Am. Chem. Soc., 86, 951–952 (1964).CrossRefGoogle Scholar
  11. 11.
    A. R. Morgan, D. Skalkos, G. M. Grabo, et al., J. Med. Chem., 34, 2126–2133 (1991).PubMedCrossRefGoogle Scholar
  12. 12.
    O. E. Nasakin, A. N. Lyshchikov, Ya. S. Kayukov, and V. P. Sheverdov, Khim.-farm. Zh., 34(4), 11–23 (2000).Google Scholar
  13. 13.
    V. P. Sheverdov, V. V. Bulkin, O. V. Ershov, et al., Zh. Obshch. Khim., 72, 972–974 (2002).Google Scholar
  14. 14.
    V. P. Sheverdov, V. V. Bulkin, O. E. Nasakin, and V. A. Tafeenko, Zh. Obshch. Khim., 74, 91–93 (2004).Google Scholar
  15. 15.
    A. B. Zolotoi, V. P. Sheverdov, P. M. Lukin, et al., Izv. Akad. Nauk SSSR, Ser. Khim., 2867 (1989).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2008

Authors and Affiliations

  • V. P. Sheverdov
    • 1
  • O. V. Ershov
    • 1
  • O. E. Nasakin
    • 1
  1. 1.Ul’yanov Chuvash State UniversityChuvash RepublicRussia

Personalised recommendations